# Adjunctive individual meaning-centered psychotherapy plus protocolized fluoxetine for moderate-to-severe adolescent depression

**Authors:** Li-Li Sheng, Min Zhang

PMC · DOI: 10.3389/fpsyt.2025.1748005 · 2026-01-08

## TL;DR

Adding individual meaning-centered psychotherapy to standard fluoxetine treatment improves depression outcomes in adolescents.

## Contribution

This study demonstrates that IMCP, when combined with protocolized fluoxetine, enhances treatment outcomes for adolescents with moderate-to-severe depression.

## Key findings

- IMCP+fluoxetine showed earlier and larger reductions in depressive symptoms compared to TAU.
- IMCP led to greater improvements in anxiety, self-esteem, and perceived meaning in life.
- No serious adverse events occurred in either group, and AE frequencies were low.

## Abstract

To determine whether individual, adapted Meaning-Centered Psychotherapy (IMCP), delivered alongside protocolized fluoxetine, improves depressive symptoms and related outcomes in adolescents with moderate-to-severe depression.

Among 168 adolescents with DSM-5-TR depressive disorder and Patient Health Questionnaire–9 modified for Adolescents (PHQ-A) ≥10, all receiving protocolized fluoxetine, participants were randomized to IMCP+TAU or TAU; the IMCP group completed seven weekly 60-minute sessions. The primary outcome was PHQ-A; secondary outcomes were the Zung Self-Rating Anxiety Scale (SAS), Clinical Global Impressions - Severity and - Improvement (CGI-S/CGI-I), Children’s Global Assessment Scale (CGAS), Rosenberg Self-Esteem Scale (RSES), and Meaning in Life Questionnaire - Presence and Search subscales (MLQ-Presence/Search). Serious adverse events (SAEs) and adverse events (AEs) were recorded throughout the 12-week study period.

Across 12 weeks, the IMCP group showed earlier and larger reductions in depressive symptoms (PHQ-A) than TAU, with advantages evident by week 4 and maintained at weeks 8 and 12; severity distributions shifted more toward milder categories in IMCP. Anxiety (SAS) declined in both groups, with greater improvement in IMCP. Clinician ratings reflected the same pattern: IMCP achieved lower illness severity (CGI-S) and better early improvement (CGI-I), and greater functional gains (CGAS) throughout follow-up. Self-esteem (RSES) rose more in IMCP. Meaning in life-Presence (MLQ-Presence) increased more with IMCP, while Search (MLQ-Search) changed minimally and similarly across groups. Neither group experienced SAEs, and AE frequencies were low and did not differ meaningfully between groups.

Adjunctive IMCP with standardized fluoxetine produced greater 12-week improvements than TAU in symptoms, clinician ratings, functioning, self-esteem, and felt meaning, supporting IMCP as a feasible and effective adjunct.

## Linked entities

- **Chemicals:** fluoxetine (PubChem CID 3386)
- **Diseases:** depressive disorder (MONDO:0002050)

## Full-text entities

- **Diseases:** depression (MESH:D003866), Anxiety (MESH:D001007), DSM-5-TR (MESH:D008232)
- **Chemicals:** fluoxetine (MESH:D005473)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12823874/full.md

---
Source: https://tomesphere.com/paper/PMC12823874